-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belapectin in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belapectin in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belapectin in Head And Neck Squamous...
-
Product Insights
NewNet Present Value Model: Compugen Ltd’s COM-701
Empower your strategies with our Net Present Value Model: Compugen Ltd's COM-701 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewArrhythmias – Drugs In Development, 2024
Empower your strategies with our Arrhythmias – Drugs In Development, 2024 report and make more profitable business decisions. An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness; fainting or nearly fainting; sweating; shortness of breath; and chest pain. Treatment includes anti-arrhythmics and anticoagulants. The Arrhythmias drugs in development market research report provide...
-
Product Insights
NewOcular Melanoma – Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
NewLiver Cirrhosis – Drugs In Development, 2024
Empower your strategies with our Liver Cirrhosis – Drugs In Development, 2024 report and make more profitable business decisions. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver, which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness, and nausea. Treatment includes liver transplant surgery. The...
-
Product Insights
NewRecurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent head and neck squamous cell carcinoma (HNSCC) refers to the return of cancer in the head and neck region after initial treatment. HNSCC includes tumors of the oral cavity, pharynx, larynx, and other structures. Recurrence can occur locally, regionally, or distantly. Management of recurrent HNSCC depends on the specific circumstances, including the location and extent...
-
Product Insights
NewPulmonary Arterial Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
-
Product Insights
NewPortal Hypertension – Drugs In Development, 2024
Empower your strategies with our Portal Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Portal hypertension is increased pressure within the portal venous system. It is determined by the increased portal pressure gradient (the difference in pressures between the portal venous pressure and the pressure within the inferior vena cava or the hepatic vein. This pressure gradient is normally less than or equal to 5 mmHg. A pressure gradient of 6 mmHg or more between the...
-
Product Insights
NewPlaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024
Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a...